An open, multicenter clinical study on cetuximab combined with intensity modulated radiotherapy (IMRT) plus concurrent chemotherapy in nasopharyngeal carcinoma (NPC): Preliminary report.

Lu, Tai Xiang; Zhao, Chong; Chen, C.; Gao, Li; Lang, Jin Yi; Pan, Jiadong; Hu, Chaosu; Jin, Feng; Wang, R.; Xie, Changchun

doi:10.1200/jco.2010.28.15_suppl.5577

Cited by 10 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gastrointestinal adverse effects (vomiting, nausea and stomatitis) were reported to be mild in their study. The ENCORE study [10] also demonstrated promising results using the combined modality of IMRT plus concurrent cisplatin and cetuximab in LA NPC patients. All patients achieved CR 3 months after the treatment.…”

Section: Discussionmentioning

confidence: 90%

See 1 more Smart Citation

Weekly cetuximab concurrent with IMRT aggravated radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma: Results of a randomized phase II study

Liu

Dou

et al. 2015

Oral Oncology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 90%

“…The findings have stimulated attentions in integrating cetuximab into current treatment regimens in NPC patients [10][11][12]. The schedule of concurrent cetuximab-cisplatin-radiotherapy had certified to be more effective than their former outcomes without cetuximab in a Hong Kong study [11], but more adverse events were observed.…”

Section: Introductionmentioning

confidence: 96%

Weekly cetuximab concurrent with IMRT aggravated radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma: Results of a randomized phase II study

Liu

Dou

et al. 2015

Oral Oncology

View full text Add to dashboard Cite

“…However, studies of HNSCC should be interpreted with caution when extrapolating to NPC because of their different biological behaviors. The schedule of concurrent cetuximab-cisplatin radiotherapy had proven to be effective in NPC [24,25]. However, we only found a few studies that reported their experience with cetuximab in the treatment of R/M NPC.…”

Section: Discussionmentioning

confidence: 93%

Cetuximab in combination with chemoradiotherapy in the treatment of recurrent and/or metastatic nasopharyngeal carcinoma

Shen

et al. 2016

Anti-Cancer Drugs

View full text Add to dashboard Cite

The aim of the study was to assess the efficacy and toxicity of cetuximab in the combined treatment for patients with recurrent and/or metastatic nasopharyngeal carcinoma (R/M NPC). Between March 2007 and November 2011, a total of 30 R/M NPC patients treated with comprehensive therapy including cetuximab were retrospectively enrolled. Intensity-modulated radiation therapy was delivered in recurrent disease with a median dose of 60 Gy. Chemotherapy regimens included TP/TPF (docetaxel 60-75 mg/m d1+DDP 25 mg/m d1-3±5-FU 500 mg/m/day with 120-h infusion), GP (gemcitabine 1.0 g/m d1, d8+DDP 25 mg/m d1-3), and PC (paclitaxel 60 mg/m/week d1+carboplatin AUC 2/week d1). Acute and late toxicities were documented by the radiation oncologists. The median age of the patients was 44 years (range 26-62). A total of 21 patients (70%) achieved response (CR+PR). The median survival time, time to progression, and 2-year overall survival were 23.6, 12.2 months, and 53.3%, respectively. Cetuximab appears to be effective and well tolerated when combined with chemoradiation therapy for the treatment of R/M NPC.

show abstract

“…In NPC, a phase II study showed that cetuximab combined with carboplatin demonstrates clinical activity for recurrent or metastatic NPC patients with previous treatment failure with platinum-based therapy [ 15 ]. The preliminary report of the ENCORE study demonstrated a promising clinical response in using cetuximab combined with CCRT in NPC [ 16 ]. A phase II study conducted by Ma et al reported that concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced NPC was feasible and preliminary survival outcomes compared favorably with historic data [ 17 ].…”

Section: Introductionmentioning

confidence: 99%

Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case–control study

Chen

Tang

et al. 2017

BMC Cancer

View full text Add to dashboard Cite

BackgroundThis study aimed to evaluate the long-term outcome and toxicities in patients with locoregionally advanced nasopharyngeal carcinoma (NPC) treated by concurrent chemoradiotherapy (CCRT) with/without adding cetuximab.MethodsA total of 62 patients treated with CCRT plus cetuximab were matched with 124 patients treated with CCRT alone by age, sex, pathological type, T category, N category, disease stage, radiotherapy (RT) technique, Epstein-Barr virus (EBV) DNA levels, and Eastern Cooperative Oncology Group (ECOG). Overall survival (OS), progression-free survival (PFS), locoregional recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS) were assessed using the Kaplan–Meier method and log-rank test. Treatment toxicities were clarified and compared between two groups.ResultsA total of 186 well-balanced stage II to IV NPC patients were retrospectively analyzed (median follow-up, 76 months). Compared to CCRT alone, adding cetuximab resulted in more grade 3 to 4 radiation mucositis (51.6% vs. 23.4%; P < 0.001). No differences were found between the CCRT + cetuximab group and the CCRT group in 5-year OS (89.7% vs. 90.7%, P = 0.386), 3-year PFS (83.9% vs. 88.7%, P = 0.115), the 3-year LRFS (95.0% vs. 96.7%, P = 0.695), and the 3-year DMFS (88.4% vs 91.9%, P = 0.068). Advanced disease stage was the independent prognostic factor predicting poorer OS and PFS.ConclusionAdding cetuximab to CCRT did not significantly improve benefits in survival in stage II to IV NPC and exacerbated acute mucositis and acneiform rash. Further investigations are warranted.

show abstract

An open, multicenter clinical study on cetuximab combined with intensity modulated radiotherapy (IMRT) plus concurrent chemotherapy in nasopharyngeal carcinoma (NPC): Preliminary report.

Cited by 10 publications

References 0 publications

Weekly cetuximab concurrent with IMRT aggravated radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma: Results of a randomized phase II study

Weekly cetuximab concurrent with IMRT aggravated radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma: Results of a randomized phase II study

Cetuximab in combination with chemoradiotherapy in the treatment of recurrent and/or metastatic nasopharyngeal carcinoma

Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case–control study

Contact Info

Product

Resources

About